The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Does MRD-guided therapy have potential in CLL?
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the potential of measurable residual disease (MRD)-guided therapy in chronic lymphocytic leukemia (CLL). Dr Davids notes that comparative studies are needed to demonstrate the benefit of MRD-guided therapy over fixed-duration therapy, and upcoming trials, including the CLL18 study and a US-based study of zanubrutinib-based regimens, will help address this. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
